However, AngII treatment of hAPPswe/PSEN1dE9 and their WT control animals resulted in a significantly increased incidence of AAAs, with the AAA incidence of AngII-treated WT control animals doubling compared to that of AngII-treated hAPPswe/PSEN1dE9 mice (Table 1), causing a significant genotypic effect (Figure 3C, p = 0.007). The gene discussed is AGT; the disease is achalasia-alacrima syndrome.